Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
Key Highlights
- ➤Acurx signs 12-month sponsored media series with New to The Street
- ➤IBZ-PATHFINDER Phase 2 trial enrolls first patient in multiply-recurrent CDI
- ➤FDA guidance supports potential single Phase 3 trial for IBZ's NDA
- ➤Programming reaches investors across four regions through Bloomberg Television
- ➤New to The Street CEO Vince Caruso calls Acurx a compelling public-markets story
Expert Statements
Vince Caruso, Co-Founder & CEO of New to The Street
“Some of the most compelling stories in the public markets come from companies solving problems the world can't afford to ignore”
Vince Caruso, Co-Founder & CEO of New to The Street
“Acurx is one of them. For the next 12 months, investors on four continents will hear directly from the team developing a new class of antibiotics, every month and on every screen they use.”
NEW YORK CITY, NY / ACCESS Newswire / October 5, 2026 / Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) has signed a 12-month media series with New to The Street. The series will bring the Company's work on a new class of antibiotics to investors in the United States, Latin America, the Middle East and North Africa (MENA) and Southeast Asia.
Each month, Acurx leadership will appear in a long-form interview broadcast on Bloomberg Television as sponsored programming in all four regions. Each interview will also be distributed on New to The Street TV, one of the largest YouTube channels dedicated to public companies. Television commercials and accredited investor events round out the program and give Acurx management direct access to qualified investors.
Get started
Create a free account to read the full story.